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Iron uptake and release by cells are tightly regulated processes. The expression of ferritin, TfR, DMT1, IREG 1 and several other genes is regulated posttranscriptionally by the IRE/IRP system and in some cases the molecules involved are subjected to transcriptional and/or post-translational regulation. At the whole body level regulation is also very important. Intestinal iron uptake must be tightly controlled since iron excretion is very limited and, since excess iron is toxic, iron absorption is finely attuned to bone iron needs. The hemochromatosis gene (HFE) and its protein product play an important role in determining how the intestine responds to body iron requirements, but the precise mechanisms involved have yet to be elucidated.
IRON OVERLOAD DISEASE
Body iron accumulation and resultant tissue injury arise from a failure of the above regulatory processes with increased iron absorption, or from iron administration, especially repeated blood transfusions. Often, as for example in Thalassemia major, both factors apply, the increased iron absorption caused by anemia. In hereditary hemochromatosis (HHC) the increased iron absorption is due to mutations in HFE although the precise pathobiological mechanisms remain unresolved.
Once a critical threshold level of iron in tissues is achieved, hepatic stellate cell activation and proliferation occurs, resulting in increased collagen synthesis and progression to fibrosis. The hepatocyte iron concentration necessary to induce formation of collagen and progression of fibrosis is dynamic and influenced by environmental factors, especially alcohol intake, but also by other disorders, such as nonalcoholic steatohepatitis and viral hepatitis. Fibrosis and cirrhosis of the liver are usually associated with an hepatic iron con-
NORMAL IRON ABSORPTION AND PHYSIOLOGY
Iron is essential for life because almost all eukaryotic cells require iron for vital enzyme function and critical metabolic pathways. These enzymes include the cytochrome enzymes and iron-sulfur proteins required for electron transport in mitochondria, in DNA synthesis and in oxygen binding and transport in hemoglobin and myoglobin. However, iron is also able to catalyze the formation of superoxide and hydroxyl radicals, thus its concentration must be kept within defined physiological limits to prevent cellular damage.
The recent application of genetic and molecular approaches to the study of inherited disorders of iron metabolism has unravelled many of the fundamental processes and pathways in normal iron trafficking in mammalian tissues. These are shown diagrammatically in Fig. 1 . Iron is absorbed across the epithelial cells of the proximal small intestine in either a heme or nonheme form. Little is known about the absorption of heme iron but non-heme ferrous iron uptake is facilitated by the divalent metal transporter DMT1. 1 Ferric iron must first be reduced by a plasma membrane reductase. Intracellularly, iron is either stored in ferritin or transported across the basolateral membrane by the membrane protein IREG 1 (also known as ferroprotein). The membrane-bound ceruloplasmin homolog, hephaestin, is also required but its precise role is unknown. Plasma transferrin binds iron on the baso-lateral surface and delivers it to body tissues, primarily reticulocytes and the liver via the transferrin receptor (TfR). The Tf/TfR complex is internalized by receptor-mediated endocytosis. The iron is then released by endosomal acidification and transported across the endosomal membrane by DMT1 where it is used for metabolic processes or stored as ferritin. Quantitatively, most iron is incorporated into hemoglobin within red blood cells which, at the end of their life span, are phagocytosed by Kupffer cells and macrophages and the iron is returned to the circulation. Recent data suggest that the main iron A classification of iron overload diseases is given in Table 1 . The prevalence of the various diseases varies widely geographically, even within the category of hereditary hemochromatosis (HHC). HFE-related HHC occurs almost exclusively in populations of northern European extraction, whereas non-HFE related HHC is more common in southern Europe, especially southern Italy. In Asia, the chronic hemolytic anaemias are the most common cause of iron overload, especially thalassemia major. It should be emphasized that moderate to severe iron overload (e.g. body iron stores of 5-25 g) is usually due to hemochromatosis, thalassemia major or sideroblastic anemia, and African iron overload. The other causes of iron overload listed in Table 1 are usually associated with lesser degrees of iron loading (less than 5 g body iron stores), although in these diseases iron may act as a significant cofactor in producing hepatic fibrosis and cirrhosis, for example fatty liver disease.
2

HEREDITARY HEMOCHROMATOSIS
The familial nature of hereditary hemochromatosis (HHC) was described by Sheldon in 1935 who, after reviewing 311 published cases of hemochromatosis, characterized the disease as an inherited inborn error of iron metabolism. Nearly 40 years later, the genetic etiology of HHC was firmly established by Simon et al. who reported the association between HHC and HLA-A3 and B7. Finally, in 1996 using positional cloning, Feder et al. described a gene initially termed HLA-H, but later renamed HFE, and two mutations C282Y and H63D, which are responsible for the majority of cases of HHC. 3 Hereditary hemochromatosis is an inherited disorder of iron metabolism that results in the abnormal absorption, accumulation and distribution of iron in tissues throughout the body. The progressive accumulation of iron in the liver, kidneys, heart, pancreas and other organs can lead to fibrosis, cirrhosis, diabetes mellitus, cardiomyopathy, and eventually, if untreated, multiorgan failure. Biochemically, an iron overload state is reflected by a persistent fasting transferrin saturation > 45% and a serum ferritin level > 350 mg/L for men and > 250 mg/L for women.
Clinical features
Non-specific signs, such as lethargy and arthralgia, are common early in the progression of hemochromatosis. Hepatomegaly is seen in over 95% of symptomatic patients, although other signs of chronic liver disease are seen less frequently. Generalized pigmentation is seen in the majority of patients but can be limited to, or is most marked in, exposed areas. Diabetes mellitus is present in 30-60% of patients with advanced disease and arthropathy in some 25% of cases. Clinical expression is affected not only by genetics, but also by environmental factors, such as oral iron intake, alcohol consumption and blood donation history, as well as physiological and pathologic blood loss. Women are affected at a later age than men, probably because of blood loss during parturition and menstruation. Due to the wide variability in expression, the diagnosis of hemochromatosis should be considered in any patient with unexplained hepatomegaly, skin pigmentation, arthropathy, diabetes mellitus, cardiomyopathy or hypogonadism.
Diagnosis
The insidious onset and high prevalence of non-specific symptoms in the early stages of disease progression requires the clinician to develop a high index of clinical suspicion and careful clinicopathologic correlation to arrive at the correct diagnosis of hemochromatosis. Causes of secondary iron overload should be excluded based on a careful history and relevant laboratory investigations (Table 1) . Criteria for the diagnosis of established hemochromatosis include at least one of the following in the absence of other known causes of iron overload:
1 Stainable hepatic iron grade 3 or 4. 2 Hepatic iron concentration > 80 mM/g (dry weight). 3 Hepatic iron index (hepatic iron concentration/age) > 1.9. 4 Removal of 5 g or more of iron by therapeutic phlebotomy without inducing iron deficiency. 5 Diagnosis of HFE-associated hemochromatosis confirmed by the demonstration of homozygosity for the C282Y mutation or compound heterozygosity for C282Y and H63D.
While the use of liver biopsy has long been the gold standard for diagnosis of hemochromatosis, its role has been changed to one of prognostic value since the elucidation of the hemochromatosis gene (HFE).The indications for liver biopsy are now generally accepted as: age > 40 years, serum ferritin > 1000 mg/L or abnormal liver function tests. 4 Current research focuses on the use of serum markers of fibrosis (which may supplant the need for liver biopsy) to determine presence or absence of cirrhosis and yield prognostic information, 5 but these are not yet in the clinical arena.
Genetics and pathobiology of hereditary hemochromatosis
HFE-related HHC is the best characterized iron overload condition. The gene affected in this disease encodes a MHC class 1-like molecule known as HFE. Most patients with HHC are homozygous for a mutation producing a single amino acid substitution of tyrosine for cysteine at position 282 (C282Y) of the HFE protein. 2 Of several other HFE mutations described, the most prevalent leads to the amino acid substitution H63D, but this alteration does not appear to result in significant iron loading in most cases. 6 The mechanisms by which mutations in HFE leads to increased intestinal iron absorption in the face of an elevated body iron content is unknown. Recent studies, however, have shown that HFE is able to associate with the TfR and thus it may play some role in regulating the entry of iron into cells. 1 This capability is lost in C282Y mutant HFE, and it is tempting to speculate that the ability of intestinal crypt cells to take up iron from plasma Tf (a means of signaling the intestine of body iron levels and hence body iron requirements) may be defective in HHC patients. Consistent with this is the important observation that the mucosal epithelium in this disorder contains remarkably little iron in comparison with patients having other forms of iron overload, despite comparable degrees of systemic iron loading. The presence of an iron-deficient mucosa in HCC could explain the observed elevated rate of iron absorption and supports the contention that there is a defect in the way the body informs the mucosal epithelium of body iron requirements in this disorder.
HFE is also expressed in reticuloendothelial cells and the same defect responsible for increased iron absorption may be responsible for enhanced efflux of iron from the macrophages of HHC patients.There is a deficiency of iron in bone marrow macrophages in HHC, and iron deposition in hepatic parenchymal cells generally is 
S194
LW Powell much more prominent than in Kupffer cells. 7 Consistent with these observations, increased efflux of iron from hemochromatotic macrophages has been demonstrated in kinetic studies, suggesting the possibility of a defect in the control of reticuloendothelial processing or release. Taken together, these observations, and other studies indicating an increased rate of transfer of mucosal iron to the plasma, suggest a systemic defect involving accelerated release of iron not only from the reticuloendothelial system but also from other tissues, including the intestinal mucosa. The precise role of HFE in cellular and body iron homeostasis remains one of the most fascinating, yet elusive, problems of contemporary trace element metabolism.
Non-HFE hereditary hemochromatosis
The genetic and basic defects in these forms of HHC are less clear. The gene responsible for juvenile hemochromatosis lies on chromosome 1q but has not yet been cloned. Adult onset non-HFE HHC has been associated with mutations in the transferrin receptor 2 gene (TfR2) on chromosome 7q22. The gene encodes a possible transmembrane protein with moderate homology to transferrin receptor and expressed mainly in the liver. Because inactivation of TfR2 causes iron overload, TfR2 is probably involved in the regulation of iron absorption, although the underlying molecular mechanisms require further study. 8 The clinical syndromes due to these non-HFE forms of HHC are similar to HFE-related HHC although juvenile hemochromatosis is more severe with clinical symptoms becoming overt before the age of 30 years due to cardiac disease and hypogonadism. 8 
Associated diseases
An increased frequency of porphyria cutanea tarda (PCT) associated with HFE has been described. The C282Y mutation is present in 44% of Australian and UK PCT patients (significantly greater than controls), with no increase in the frequency of the H63D mutation. 9, 10 In contrast, Sampietro et al. 11 report that 50% of Italian PCT patients carry the H63D compared with 24% for controls. Recent evidence suggests that C282Y carriers may have an increased risk of acute myocardial infraction and cardiovascular death. 12 It has been speculated that an iron depleted state is more protective than an iron repleted state, although the effect of HFE on coronary heart disease remains controversial.
The association of hemochromatosis with hepatocellular carcinoma is well described. In male hemochromatotics with cirrhosis, a 200-fold increase in the incidence of HCC has been documented. 2 Increased iron has also been documented in the livers of patients with primary HCC without cirrhosis.
Screening
Hereditary hemochromatosis meets the World Health Organization's criteria for population-based screening. However, due to the late onset of disease, unclear penetrance and prevalence of HFE, possible stigmatization of genetically identified affected individuals, insurance implications and other psychosocial issues, a recent expert consensus concluded that populationbased screening for HHC by genetic means is premature and further studies are needed to address these issues. 13 Currently, screening for hemochromatosis should be considered for relatives of individuals diagnosed with HHC and individuals during standard medical assessment. Once the diagnosis of HHC has been made, and the presence of C282Y established, screening of first degree relatives is indicated. If a parent is identified as homozygous C282Y, the spouse should be genotyped if they have children. If the spouse carries the C282Y mutation, further testing of children is warranted. Family members having C282Y homozygosity should be checked for serum transferrin saturation, ferritin and liver enzyme levels. Individuals presenting for a routine medical assessment should have their transferrin saturation levels measured. If greater than 45%, and verified by a second fasting sample, further investigation is warranted. 13 Recent investigations using more cost-effective biochemical approaches, for example unsaturated iron-binding capacity, show promise to replace the more costly and time-consuming measurement of transferrin saturation levels, but these are not yet widely available clinically.
As indicated there is much current interest and debate as to whether population screening for HFErelated HHC is warranted and cost-effective. Despite strong advocates, the main consensus is to await further information derived from well-designed screening programs that incorporate careful follow-up of identified HHC patients and matched controls.
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Therapy
Once the diagnosis of HHC is established, the therapy is simple and effective. Affected patients should immediately be started on a course of iron depletion and monitoring. Therapeutic phlebotomy should be performed once to twice weekly with regular monitoring of hemoglobin or hematocrit and serum ferritin levels after each gram of iron removed (1 g = 4 donations). Iron depletion is continued until serum ferritin levels are below 50 mg/L and transferrin saturation is 50% or less. Maintenance phlebotomy is performed three to four times yearly in order to maintain ferritin levels below 50 mg/L. Blood removed from asymptomatic patients with normal liver function tests is now used by the Red Cross Blood Transfusion Service in many countries, including Australia. Since the natural progression of C282Y/H63D compound heterozygotes and C282Y homozygotes who are nonexpressing is poorly understood, it is suggested that these individuals become regular blood donors and have their iron indices monitored on a regular basis.
The management objectives for HHC are summarized in Table 2 .
Secondary iron overload
The causes of secondary iron overload are listed in Table 1 .
Phlebotomy is useful only in certain forms of secondary iron overload. It has been used in African iron overload and porphyria cutanea tarda with reduction in morbidity and mortality. No systematic, randomised controlled studies have been done in secondary iron overload states associated with chronic liver diseases to evaluate long-term outcomes of iron removal therapy. In secondary iron overload associated with ineffective erythropoiesis, iron chelation therapy with parenteral deferoxamine is the treatment of choice. Multiple studies have documented the efficacy of deferoxamine in preventing the complications of iron overload in bthalassemia. Deferoxamine mesylate (Desferal; Novartis Pharmaceuticals Corporation) is the only approved iron chelation agent that is widely available. Usually it is administered subcutaneously, using an implanted minipump, by continuous infusions over a 24-hour cycle at a dose of 20-40 mg/kg/day. A total dose of about 2 g per 24 h usually achieves maximum urinary iron excretion. Chelation therapy to reduce hepatic iron concentrations below 15 000 mg/g dry weight significantly reduces the risk of clinical disease. However, the aim of chelation therapy should be more ambitious and should attempt to achieve and maintain near normal hepatic iron concentrations. The application of deferoxamine therapy is limited by cost (particularly in developing countries), the need for a parenteral route of therapy, discomfort and inconvenience (a challenging prospect in young patients), and neurotoxicity. In addition, a variety of opportunistic bacterial infections have been described after prolonged chelation therapy. 13 Monitoring iron reduction in patients with secondary iron overload is a challenge. In contrast to HH, where serum ferritin reliably reflects iron burden during therapy, ferritin levels are misleading in secondary overload cases. In many patients, it may be necessary to repeat the liver biopsy to assess the progress of therapy and ensure adequate chelation. The recent advent of high Tesla magnetic resonance imaging instruments showed some initial promise as a non-invasive way to estimate hepatic iron levels, but it has proven to be inaccurate when there is marked iron overload or hepatic fibrosis/cirrhosis. 13 In selected patients with Thalassemia major, allogeneic bone marrow transplantation offers the possibility of permanent cure of the hematologic disorder. However, the preexisting iron overload persists after the transplantation and such patients may be recommended for phlebotomy with the expectation that the bone marrow is capable of enhanced erythropoiesis. As in patients treated by chelation, the liver iron concentration provides an accurate, quantitative means for monitoring iron balance. 
